materially false statements

$MEDP faces class action lawsuit alleging executives misrepresented book-to-bill ratio; investors must act by June 5, 2026.

Class action lawsuit filed against Babcock & Wilcox alleges executives made false statements and concealed shareholder conflicts in Applied Digital contract. Eligible shareholders from November 2025-March 2026 may recover losses.

Class action lawsuit filed against Medpace Holdings alleging executives made false statements about book-to-bill ratio from April 2025 to February 2026.

Gross Law Firm alerts $POET investors of June 29 deadline for securities class action over alleged tax status misrepresentation and disclosure failures.

Class action lawsuit filed against Nektar Therapeutics alleging false statements about REZOLVE-AA trial enrollment protocols. Investors harmed between February-December 2025 can join case.

Class action lawsuit filed against Gossamer Bio for allegedly concealing design flaws in Phase 3 PROSERA study, claiming investors purchased stock at artificially inflated prices.

Medpace faces class action lawsuit over allegedly inflated book-to-bill ratio claims during April 2025-February 2026 period; lead plaintiff deadline set for June 5, 2026.

Class action lawsuit filed against Navan alleging its October 2025 IPO prospectus contained false statements about sales and marketing expense requirements.

Class action filed against Navan alleging IPO prospectus contained false statements regarding sales and marketing expenses needed for revenue growth.

Rosen Law Firm alerts investors in $CWH securities to May 11 deadline in class action alleging false inventory management statements and overstated demand.

Class action lawsuit filed against Coty Inc. alleging executives made false statements about growth prospects and concealed segment challenges during November 2025-February 2026 period.

Class action lawsuit filed against $MDPC alleging executives overstated book-to-bill ratio at approximately 1.15 despite contrary internal data from April 2025 to February 2026.

Class action lawsuit filed against Gossamer Bio for alleged false statements regarding Phase 3 PROSERA study results and concealed trial design issues at Latin American sites.

Class action lawsuit filed against Medpace Holdings alleging executives made false statements about financial metrics from April 2025 to February 2026.

Law firm announces lead plaintiff deadlines for shareholder class actions against $AQST, $NKTR, and $EOSE over alleged false statements and misleading guidance.

Law firm announces shareholder lawsuit deadlines (May 2026) against $ALIT, $GO, $GEMI over alleged materially false statements on financials, dividends, and business viability.

Class actions filed against $IT, $PSIX, $GEMI, $HTGC alleging disclosure failures. Investors have until mid-to-late May 2026 for lead plaintiff motions.

Class action lawsuit filed against Coty Inc. alleging executives made false statements about growth prospects during November 2025-February 2026 period.

BlackRock TCP Capital Corp. faces class action lawsuit alleging materially false statements on valuations and NAV. Shareholders can register as lead plaintiff by April 6, 2026.

Law firm files class action against $IT for allegedly false statements on contract value, revenue projections, and consulting segment performance between February 2025-2026.